AlloSource® Announces Positive Clinical Results for AlloTrue™ - Low-Dose Irradiated Tendons

AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that its tendons processed using its proprietary AlloTrue™ cleansing process, as well as low-dose irradiation, are effective when used in anterior cruciate ligament reconstruction (ACLR).

The study results found BioCleanse graft processing, younger patient age, BPTB allografts and irradiation over 1.8 Mrad were all associated with a higher risk of clinical failure and subsequent revision surgery. AlloSource tendons are treated with irradiation doses between .95-1.4 Mrad. Also, the use of AlloTrue did not significantly affect revision rate.

Please click on the PDF to read the full press release.

Download PDF